Prioritizing global strategies to cure MS
- PMID: 39212111
- DOI: 10.1177/13524585241272987
Prioritizing global strategies to cure MS
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: C.C. has no disclosures. M.T. has received compensation for consulting services, speaking honoraria and research support from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Immunic Therapeutics, Janssen, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Viela Bio, and Teva Pharmaceuticals. Data Safety Monitoring Board for Parexel and UCB Biopharma, Relapse Adjudication Committee for IMCYSE SA.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
